CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis

Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to malignancy has been steadily recognized. circRNA expression was obtained by circRNA sequencing of prostate cancer. circRNA and its function were...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Epigenetics Ročník 18; číslo 1; s. 2178802
Hlavní autori: Dai, Xiyu, Chen, Xinan, Chen, Wensun, Ou, Yuxi, Chen, Yiling, Wu, Siqi, Zhou, Quan, Yang, Chen, Zhang, Limin, Jiang, Haowen
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Taylor & Francis 31.12.2023
Taylor & Francis Group
Predmet:
Alcohol Oxidoreductases
Animals
Cell Line, Tumor
Cell Movement
Cell Proliferation - genetics
circDHRS3
circRNA
DNA Methylation
Gene Expression Regulation, Neoplastic
Homeodomain Proteins - genetics
Humans
In Situ Hybridization, Fluorescence
Male
MEIS2
Mice
Mice, Nude
MicroRNAs - genetics
prostate cancer
Prostatic Neoplasms - genetics
Research Paper
RNA, Circular - genetics
Transcription Factors - genetics
prostate cancer
circRNA
MEIS2
circDHRS3
ISSN:1559-2294, 1559-2308, 1559-2308
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to malignancy has been steadily recognized. circRNA expression was obtained by circRNA sequencing of prostate cancer. circRNA and its function were further analysed. The results were verified by qRT-PCR, RIP assay, FISH, RNA pulldown, WB, CCK-8, colony formation assay and wound-healing assay. BALB/c Nude mice were used for xenograft hosts. Low expression of circDHRS3 was assessed in prostate cancer. Overexpression of circDHRS3 inhibited prostate cancer growth and migration in vitro. Additionally, miR-421 was shown to be the downstream target of circDHRS3, as shown by fluorescence in situ hybridization and dual-luciferase experiments. The rescue assay results for the PC3 and Du145 cell lines demonstrated that circDHRS3 inhibits prostate cancer cell lines' ability to proliferate and metastasize by modulating MEIS2 expression through the circDHRS3/miR-421/MEIS2 axis. In vivo investigations confirmed that the overexpression of circDHRS3 could inhibit both the lung and bone metastasis of prostate cancer cells. circDHRS3 has the potential to become a biomarker and a targeted therapeutic site for prostate cancer, particularly in the malignant stage. Our study indicates that circDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.
AbstractList Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to malignancy has been steadily recognized. circRNA expression was obtained by circRNA sequencing of prostate cancer. circRNA and its function were further analysed. The results were verified by qRT-PCR, RIP assay, FISH, RNA pulldown, WB, CCK-8, colony formation assay and wound-healing assay. BALB/c Nude mice were used for xenograft hosts. Low expression of circDHRS3 was assessed in prostate cancer. Overexpression of circDHRS3 inhibited prostate cancer growth and migration in vitro. Additionally, miR-421 was shown to be the downstream target of circDHRS3, as shown by fluorescence in situ hybridization and dual-luciferase experiments. The rescue assay results for the PC3 and Du145 cell lines demonstrated that circDHRS3 inhibits prostate cancer cell lines' ability to proliferate and metastasize by modulating MEIS2 expression through the circDHRS3/miR-421/MEIS2 axis. In vivo investigations confirmed that the overexpression of circDHRS3 could inhibit both the lung and bone metastasis of prostate cancer cells. circDHRS3 has the potential to become a biomarker and a targeted therapeutic site for prostate cancer, particularly in the malignant stage. Our study indicates that circDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.
Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to malignancy has been steadily recognized. circRNA expression was obtained by circRNA sequencing of prostate cancer. circRNA and its function were further analysed. The results were verified by qRT-PCR, RIP assay, FISH, RNA pulldown, WB, CCK-8, colony formation assay and wound-healing assay. BALB/c Nude mice were used for xenograft hosts. Low expression of circDHRS3 was assessed in prostate cancer. Overexpression of circDHRS3 inhibited prostate cancer growth and migration in vitro. Additionally, miR-421 was shown to be the downstream target of circDHRS3, as shown by fluorescence in situ hybridization and dual-luciferase experiments. The rescue assay results for the PC3 and Du145 cell lines demonstrated that circDHRS3 inhibits prostate cancer cell lines' ability to proliferate and metastasize by modulating MEIS2 expression through the circDHRS3/miR-421/MEIS2 axis. In vivo investigations confirmed that the overexpression of circDHRS3 could inhibit both the lung and bone metastasis of prostate cancer cells. circDHRS3 has the potential to become a biomarker and a targeted therapeutic site for prostate cancer, particularly in the malignant stage. Our study indicates that circDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to malignancy has been steadily recognized. circRNA expression was obtained by circRNA sequencing of prostate cancer. circRNA and its function were further analysed. The results were verified by qRT-PCR, RIP assay, FISH, RNA pulldown, WB, CCK-8, colony formation assay and wound-healing assay. BALB/c Nude mice were used for xenograft hosts. Low expression of circDHRS3 was assessed in prostate cancer. Overexpression of circDHRS3 inhibited prostate cancer growth and migration in vitro. Additionally, miR-421 was shown to be the downstream target of circDHRS3, as shown by fluorescence in situ hybridization and dual-luciferase experiments. The rescue assay results for the PC3 and Du145 cell lines demonstrated that circDHRS3 inhibits prostate cancer cell lines' ability to proliferate and metastasize by modulating MEIS2 expression through the circDHRS3/miR-421/MEIS2 axis. In vivo investigations confirmed that the overexpression of circDHRS3 could inhibit both the lung and bone metastasis of prostate cancer cells. circDHRS3 has the potential to become a biomarker and a targeted therapeutic site for prostate cancer, particularly in the malignant stage. Our study indicates that circDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.
Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to malignancy has been steadily recognized. circRNA expression was obtained by circRNA sequencing of prostate cancer. circRNA and its function were further analysed. The results were verified by qRT-PCR, RIP assay, FISH, RNA pulldown, WB, CCK-8, colony formation assay and wound-healing assay. BALB/c Nude mice were used for xenograft hosts. Low expression of circDHRS3 was assessed in prostate cancer. Overexpression of circDHRS3 inhibited prostate cancer growth and migration . Additionally, miR-421 was shown to be the downstream target of circDHRS3, as shown by fluorescence hybridization and dual-luciferase experiments. The rescue assay results for the PC3 and Du145 cell lines demonstrated that circDHRS3 inhibits prostate cancer cell lines' ability to proliferate and metastasize by modulating MEIS2 expression through the circDHRS3/miR-421/MEIS2 axis. investigations confirmed that the overexpression of circDHRS3 could inhibit both the lung and bone metastasis of prostate cancer cells. circDHRS3 has the potential to become a biomarker and a targeted therapeutic site for prostate cancer, particularly in the malignant stage. Our study indicates that circDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis.
Author Chen, Xinan
Zhou, Quan
Dai, Xiyu
Yang, Chen
Chen, Yiling
Chen, Wensun
Jiang, Haowen
Zhang, Limin
Wu, Siqi
Ou, Yuxi
Author_xml – sequence: 1
  givenname: Xiyu
  surname: Dai
  fullname: Dai, Xiyu
  organization: Huashan Hospital, Fudan University
– sequence: 2
  givenname: Xinan
  surname: Chen
  fullname: Chen, Xinan
  organization: Huashan Hospital, Fudan University
– sequence: 3
  givenname: Wensun
  surname: Chen
  fullname: Chen, Wensun
  organization: Huashan Hospital, Fudan University
– sequence: 4
  givenname: Yuxi
  surname: Ou
  fullname: Ou, Yuxi
  organization: Huashan Hospital, Fudan University
– sequence: 5
  givenname: Yiling
  surname: Chen
  fullname: Chen, Yiling
  organization: Huashan Hospital, Fudan University
– sequence: 6
  givenname: Siqi
  surname: Wu
  fullname: Wu, Siqi
  organization: Huashan Hospital, Fudan University
– sequence: 7
  givenname: Quan
  surname: Zhou
  fullname: Zhou, Quan
  organization: Huashan Hospital, Fudan University
– sequence: 8
  givenname: Chen
  surname: Yang
  fullname: Yang, Chen
  email: YangC_Huashan@163.com
  organization: Fudan University
– sequence: 9
  givenname: Limin
  surname: Zhang
  fullname: Zhang, Limin
  email: zhalim@fudan.edu.cn
  organization: Fudan University
– sequence: 10
  givenname: Haowen
  surname: Jiang
  fullname: Jiang, Haowen
  email: haowj_sh@fudan.edu.cn
  organization: Fudan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36840946$$D View this record in MEDLINE/PubMed
BookMark eNqFkktvEzEUhS1URB_wE0CzZDOJXzO2hYRAodBIRUgtrC2P7UlczdjBdqD99_U0SUVZwMrWved81_I9p-DIB28BeI3gDEEO56hpBMaCzjDEZIYR4xziZ-BkqteYQH50uBfRMThN6QZCSlohXoBj0nIKBW1PwLhwUX-6uLomlfNr17mcqk0MKatsK628trHSdhim4uB6G1V2wVfKm2q0WRVdcqnK6xi2q3U5i-kAnI_uqqYYzb-eL69xpW5degme92pI9tX-PAM_Pp9_X1zUl9--LBcfL2vdEJprghrcCWqxMAR31PJGmdKBpGWUMtV2zOC26xuNGaG057aIIVKIMqutMZicgeWOa4K6kZvoRhXvZFBOPhRCXEkVs9ODlRD1LTSCGy4sNb3gXEMsIGuQUpghWljvd6zNthut0dbnqIYn0Kcd79ZyFX5JIThsWVsAb_eAGH5ubcpydGn6U-Vt2CaJGYeQCY55kb75c9bjkMO-iqDZCXTZUYq2f5QgKKdcyEMu5JQLuc9F8b37y6ddflhlebIb_uv-sHM734c4qt8hDkZmdTeE2McSEpck-TfiHt_Lz6c
CitedBy_id crossref_primary_10_3389_fped_2024_1500152
crossref_primary_10_1002_cnr2_2064
crossref_primary_10_2478_enr_2024_0006
crossref_primary_10_3389_fonc_2024_1358422
crossref_primary_10_1093_mutage_gead027
crossref_primary_10_1186_s40001_025_02382_0
crossref_primary_10_1080_15384047_2024_2399363
crossref_primary_10_1038_s41419_023_06050_1
crossref_primary_10_1515_tjb_2024_0122
crossref_primary_10_1016_j_clnves_2025_100021
crossref_primary_10_1016_j_ijbiomac_2025_142912
crossref_primary_10_1080_1354750X_2024_2445804
crossref_primary_10_2174_0929867330666230531095850
crossref_primary_10_1002_mog2_61
crossref_primary_10_1016_j_ijpx_2025_100356
Cites_doi 10.1096/fasebj.7.1.7678559
10.1111/cas.13857
10.1038/s41419-021-03977-1
10.1016/j.canlet.2019.12.014
10.1158/1078-0432.CCR-12-0373
10.1186/s12943-019-1041-z
10.1016/j.eururo.2018.03.028
10.1038/s41420-022-00865-1
10.1038/s41419-021-04053-4
10.1158/1078-0432.CCR-17-3673
10.1158/1078-0432.CCR-18-3230
10.1016/j.molcel.2013.08.017
10.1016/j.molcel.2016.11.034
10.3322/caac.21590
10.1186/s12943-021-01480-x
10.1038/s41576-019-0158-7
10.1016/j.gendis.2017.01.003
10.1038/s41416-023-02183-4
10.3322/caac.21338
10.1038/s41419-019-2028-9
10.1016/j.omtn.2021.01.009
10.1038/s41580-020-0243-y
10.1016/j.ymthe.2022.01.022
10.1016/j.molcel.2014.08.019
10.1186/s12943-019-0941-2
10.1002/dvdy.24016
ContentType Journal Article
Copyright 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023
2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 The Author(s)
Copyright_xml – notice: 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023
– notice: 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. 2023 The Author(s)
DBID 0YH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1080/15592294.2023.2178802
DatabaseName Taylor & Francis Free Journals (Free resource, activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
– sequence: 4
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Zoology
DocumentTitleAlternate X. DAI ET AL
EISSN 1559-2308
ExternalDocumentID oai_doaj_org_article_01f60d98d89e4df988c0290751aa2714
PMC9980676
36840946
10_1080_15592294_2023_2178802
2178802
Genre Research Article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0BK
0YH
30N
4.4
53G
5GY
AAJMT
ABCCY
ABFIM
ABPAQ
ABPEM
ABXYU
ACGFS
ACTIO
ADBBV
ADCVX
ADGTB
AEISY
AENEX
AEOZL
AEPSL
AEXWM
AEYOC
AFRVT
AGDLA
AHDZW
AIJEM
AIYEW
AKBVH
AKOOK
ALMA_UNASSIGNED_HOLDINGS
ALQZU
AOIJS
AQRUH
AQTUD
AVBZW
BAWUL
BLEHA
CCCUG
DGEBU
DIK
DKSSO
E3Z
EBS
EMOBN
F5P
GROUPED_DOAJ
GTTXZ
GX1
H13
HYE
IPNFZ
KYCEM
LJTGL
M4Z
O9-
OK1
P2P
RPM
SNACF
TDBHL
TEI
TFL
TFT
TFW
TQWBC
TR2
TTHFI
TUROJ
AAYXX
CITATION
0VX
AAGDL
AALDU
AAMIU
AAPUL
AAQRR
ABLIJ
ABXUL
BOHLJ
C1A
CGR
CUY
CVF
ECM
EIF
EJD
NPM
RIG
RNANH
ROSJB
RTWRZ
TBQAZ
7X8
5PM
ID FETCH-LOGICAL-c534t-3152b94e29d32b4e85adc530367447a6b7d26bf5c27344f8eb9401a147ecedd23
IEDL.DBID DOA
ISICitedReferencesCount 16
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000939557300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1559-2294
1559-2308
IngestDate Fri Oct 03 12:45:59 EDT 2025
Tue Nov 04 02:06:57 EST 2025
Thu Oct 02 10:09:23 EDT 2025
Wed Dec 10 14:04:38 EST 2025
Sat Nov 29 03:45:04 EST 2025
Tue Nov 18 21:44:38 EST 2025
Mon Oct 20 23:47:53 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords prostate cancer
circRNA
MEIS2
circDHRS3
Language English
License open-access: http://creativecommons.org/licenses/by/4.0/: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-3152b94e29d32b4e85adc530367447a6b7d26bf5c27344f8eb9401a147ecedd23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors have been contributed equally to this work.
OpenAccessLink https://doaj.org/article/01f60d98d89e4df988c0290751aa2714
PMID 36840946
PQID 2780079828
PQPubID 23479
ParticipantIDs informaworld_taylorfrancis_310_1080_15592294_2023_2178802
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9980676
doaj_primary_oai_doaj_org_article_01f60d98d89e4df988c0290751aa2714
pubmed_primary_36840946
crossref_primary_10_1080_15592294_2023_2178802
proquest_miscellaneous_2780079828
crossref_citationtrail_10_1080_15592294_2023_2178802
PublicationCentury 2000
PublicationDate 2023-12-31
PublicationDateYYYYMMDD 2023-12-31
PublicationDate_xml – month: 12
  year: 2023
  text: 2023-12-31
  day: 31
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Epigenetics
PublicationTitleAlternate Epigenetics
PublicationYear 2023
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_9_5_1
e_1_3_9_4_1
e_1_3_9_10_1
e_1_3_9_7_1
e_1_3_9_6_1
e_1_3_9_13_1
e_1_3_9_14_1
e_1_3_9_3_1
e_1_3_9_11_1
e_1_3_9_2_1
e_1_3_9_12_1
e_1_3_9_17_1
e_1_3_9_18_1
e_1_3_9_15_1
e_1_3_9_16_1
e_1_3_9_9_1
e_1_3_9_8_1
e_1_3_9_19_1
e_1_3_9_20_1
e_1_3_9_21_1
e_1_3_9_24_1
e_1_3_9_25_1
e_1_3_9_22_1
e_1_3_9_23_1
e_1_3_9_26_1
e_1_3_9_27_1
References_xml – ident: e_1_3_9_5_1
  doi: 10.1096/fasebj.7.1.7678559
– ident: e_1_3_9_17_1
  doi: 10.1111/cas.13857
– ident: e_1_3_9_21_1
  doi: 10.1038/s41419-021-03977-1
– ident: e_1_3_9_11_1
  doi: 10.1016/j.canlet.2019.12.014
– ident: e_1_3_9_26_1
  doi: 10.1158/1078-0432.CCR-12-0373
– ident: e_1_3_9_9_1
  doi: 10.1186/s12943-019-1041-z
– ident: e_1_3_9_4_1
  doi: 10.1016/j.eururo.2018.03.028
– ident: e_1_3_9_10_1
  doi: 10.1038/s41420-022-00865-1
– ident: e_1_3_9_16_1
  doi: 10.1038/s41419-021-04053-4
– ident: e_1_3_9_18_1
  doi: 10.1158/1078-0432.CCR-17-3673
– ident: e_1_3_9_20_1
  doi: 10.1158/1078-0432.CCR-18-3230
– ident: e_1_3_9_8_1
  doi: 10.1016/j.molcel.2013.08.017
– ident: e_1_3_9_27_1
  doi: 10.1016/j.molcel.2016.11.034
– ident: e_1_3_9_2_1
  doi: 10.3322/caac.21590
– ident: e_1_3_9_22_1
  doi: 10.1186/s12943-021-01480-x
– ident: e_1_3_9_7_1
  doi: 10.1038/s41576-019-0158-7
– ident: e_1_3_9_25_1
  doi: 10.1016/j.gendis.2017.01.003
– ident: e_1_3_9_13_1
  doi: 10.1038/s41416-023-02183-4
– ident: e_1_3_9_3_1
  doi: 10.3322/caac.21338
– ident: e_1_3_9_12_1
  doi: 10.1038/s41419-019-2028-9
– ident: e_1_3_9_15_1
  doi: 10.1016/j.omtn.2021.01.009
– ident: e_1_3_9_23_1
  doi: 10.1038/s41580-020-0243-y
– ident: e_1_3_9_14_1
  doi: 10.1016/j.ymthe.2022.01.022
– ident: e_1_3_9_6_1
  doi: 10.1016/j.molcel.2014.08.019
– ident: e_1_3_9_19_1
  doi: 10.1186/s12943-019-0941-2
– ident: e_1_3_9_24_1
  doi: 10.1002/dvdy.24016
SSID ssj0043699
Score 2.4612432
Snippet Prostate cancer is the most prevalent type of cancer among men worldwide. The importance of circular RNA (circRNA) in prostate cancer and its connection to...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2178802
SubjectTerms Alcohol Oxidoreductases
Animals
Cell Line, Tumor
Cell Movement
Cell Proliferation - genetics
circDHRS3
circRNA
DNA Methylation
Gene Expression Regulation, Neoplastic
Homeodomain Proteins - genetics
Humans
In Situ Hybridization, Fluorescence
Male
MEIS2
Mice
Mice, Nude
MicroRNAs - genetics
prostate cancer
Prostatic Neoplasms - genetics
Research Paper
RNA, Circular - genetics
Transcription Factors - genetics
SummonAdditionalLinks – databaseName: Taylor & Francis Free Journals (Free resource, activated by CARLI)
  dbid: 0YH
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQAYkL-xI2GYlr-hLHseMjlFaPAxVqQSpcLMcLjdSXVyUp4ucz4yRPfRWoBzhl80RePo9nnMk3hLwNBZMWzIrUlAEcFFOrtLLCwJkPLFQ-iNzFZBPy8LA6OVGfp2jCfgqrRB86jEQRUVfj5DZ1P0fELfBLGmMKd0RYsQs2NWAQtPBNBq4J-l_Zt-WsjHkhYgpJFElRZv6J52-v2VqeIov_FQ7TP1miVwMqL61QB_f-Q9vuk7uTeUrfjXh6QG749iG5_X0dN98fkdVe09kPy6PjgjbtaVM3Q0_P8b8RsFipRQB1FD8F4M0zDJqJ406hNnTlBwPl-qanU24gOILQ_MLFqjlKOcsXn_Y_HjNqfjX9Y_L1YP_L3jKdEjaktiz4APq8ZLXinilXsJr7qjQOnsAiKTmXRtTSMVGH0iKnDgckQOEsNzmX3nrnWPGE7LTr1j8jFKBiTA4jaqTl0uW1B00jBLMV94bVJiF8HidtJzZzTKpxpvOJ9HTuSY09qaeeTMjuRux8pPO4TuA9gmBTGNm4441190NPk1tneRCZU5WrlOcuqKqyGVNgjOXGQBN4QtRlCOkhbsaEMXOKLq6pwJsZbxpmPo6haf36otdMgrEvFbjMCXk64m9TzUJEx10kRG4hc6sd20_a5jSyi4P_DRaMeP4PdX5B7uDlyIf5kuwM3YV_RW7Zn0PTd6_jBP0Navs1nA
  priority: 102
  providerName: Taylor & Francis
Title CircDHRS3 inhibits prostate cancer cell proliferation and metastasis through the circDHRS3/miR-421/MEIS2 axis
URI https://www.tandfonline.com/doi/abs/10.1080/15592294.2023.2178802
https://www.ncbi.nlm.nih.gov/pubmed/36840946
https://www.proquest.com/docview/2780079828
https://pubmed.ncbi.nlm.nih.gov/PMC9980676
https://doaj.org/article/01f60d98d89e4df988c0290751aa2714
Volume 18
WOSCitedRecordID wos000939557300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: Directory of Open Access Journals
  customDbUrl:
  eissn: 1559-2308
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0043699
  issn: 1559-2294
  databaseCode: DOA
  dateStart: 20230101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVAWR
  databaseName: Taylor & Francis Journals Complete
  customDbUrl:
  eissn: 1559-2308
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0043699
  issn: 1559-2294
  databaseCode: TFW
  dateStart: 20060101
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
– providerCode: PRVAWR
  databaseName: Taylor & Francis Open Access
  customDbUrl:
  eissn: 1559-2308
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0043699
  issn: 1559-2294
  databaseCode: 0YH
  dateStart: 20231201
  isFulltext: true
  titleUrlDefault: https://www.tandfonline.com
  providerName: Taylor & Francis
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBZb2WAvY_d6l6LBXp3YsqzL49Y1ZA8ro-1YthchSzIVNE6J3dKfvyPZDkkZ5GUvspElY_k7ks6R5e9D6FNdEG7ArUh1WUOAoiuZCsM0nLma1MLVLLdRbIKfnorFQv7YkvoKe8J6euD-xU2zvGaZlcIK6aitpRAmIxDRlbnWhEcJa5JxOQZT_RhMCxaVI8M3t5QQScd_d0Q2DXkhaxKEwyfgkYMFk51ZKZL336Mu_ZcDen8f5dbENHuGng4eJf7ct-Q5euCaF-jxn1VcL3-Jlsd-bb7Oz84L7JtLX_muxdfhVw9wMrEJmK9xWL0PmVdhn0uECuvG4qXrNJRrfYsHOR84QqXxhtOlP0spyaffT76dE6zvfPsK_ZydXBzP00FjITVlQTsYgktSSeqItAWpqBOltnAF5jVOKdes4pawqi5NoMGhAB4UznKdU-6Ms5YUr9FBs2rcIcKArtY5YKK5odzmlYPBgTFiBHWaVDpBdHzHygwE5EEH40rlA0_pCI0K0KgBmgRNNtWuewaOfRW-BAA3hQOBdswAs1KDWal9ZpUguQ2_6uL6Sd2LnahizwN8HG1FQWcNGOrGrW5aRTj451xClJugN73tbB6zYDHWZgniO1a1047dK42_jITgEDKD08He_o-Gv0NPQlt6Lsv36KBb37gP6JG57Xy7PkIPs99zSPlCHMUeB-nF7NdfHXwnUQ
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQAcGFd2F5GolruhvHseMjlK62ot1Du4iKi-U4No3UzVZJivj5zDjJarcC9QCnRLEn8uPzeMaPbwj54BMmLZgVkUk9OCgmV1FmhYE355nPnBdxEYJNyPk8OztTm3dh8Fgl-tC-I4oIuhoHNy5GD0fixriVxpjCJRGW7IFRDSAENXw7hbkW-fMX02-DNuaJCDEkUSRCmeEWz99-szU_BRr_aySmfzJFr5-o3Jiipg__R-UekQe9gUo_doh6TG656gm5-30Vlt-fkuV-WdvPs5PThJbVeZmXbUMv8eYI2KzUIoRqipsB-PECj82EnqdQHLp0rYF8TdnQPjoQPEFo-OF4WZ5EnMXj44PDU0bNr7J5Rr5ODxb7s6gP2RDZNOEtaPSU5Yo7poqE5dxlqSkgBaZJybk0IpcFE7lPLbLqcMACZJ7EJubSWVcULNklO9Wqci8IBbAYEzMZG2m5LOLcga4RgtmMO8NyMyJ86Chtez5zDKtxoeOe9nRoSY0tqfuWHJG9tdhlR-hxk8AnRME6M_Jxhw-r-ofuh7eexF5MCpUVmXK88CrL7IQpMMdiY6AKfETUJoZ0G5ZjfBc7RSc3FOD9ADgNYx_70FRuddVoJsHclwqc5hF53gFwXcxEBNddjIjcguZWPbZTqvI88IuDBw42jHj5D2V-R-7NFsdH-uhw_uUVuY9JHTvma7LT1lfuDbljf7ZlU78No_U3WZQ5xg
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zb9QwELZQOcQL9xFOI_Ga7tpx7PgR2q5aAauqLaLixXJ80Ejd7CpJET-fsZOsuhWoD_CUKPZEPj6PZ5zJNwi99xkVBsyKVOceHBRdyrQwXMOd89QXznNiY7IJMZ8Xp6fycIgmbIewyuBD-54oIurqsLhX1o8RcZPwJY1SGU5EaLYNNjVgELTwTTCdeQD5yezbqIxZxmMKySCSBpnxJ56_vWZje4os_lc4TP9kiV4NqLy0Q83u_4e-PUD3BvMUf-jx9BDdcPUjdPv7Mh6-P0aLnaoxu_tHxxmu6rOqrLoWr8J_I2CxYhMA1ODwKSA8PA9BM3HeMbQGL1ynoV5btXjIDQRXEBpfOFlURymjZPJl7-CYYv2rap-gr7O9k539dEjYkJo8Yx3o85yWkjkqbUZL5opcWyiBTVIwJjQvhaW89LkJnDoMkACVp0QTJpxx1tLsKdqql7V7jjBARWtCBdHCMGFJ6UDTcE5NwZympU4QG-dJmYHNPCTVOFdkID0dR1KFkVTDSCZoey226uk8rhP4GECwrhzYuOODZfNDDYtbTYnnUysLW0jHrJdFYaZUgjFGtIYusATJyxBSXTyM8X3mFJVd04B3I94UrPwwh7p2y4tWUQHGvpDgMifoWY-_dTMzHh13niCxgcyNfmyW1NVZZBcH_xssGP7iH9r8Ft053J2pzwfzTy_R3VDSU2O-Qltdc-Feo1vmZ1e1zZu4Vn8Dcvo4eA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CircDHRS3+inhibits+prostate+cancer+cell+proliferation+and+metastasis+through+the+circDHRS3%2FmiR-421%2FMEIS2+axis&rft.jtitle=Epigenetics&rft.au=Dai%2C+Xiyu&rft.au=Chen%2C+Xinan&rft.au=Chen%2C+Wensun&rft.au=Ou%2C+Yuxi&rft.date=2023-12-31&rft.issn=1559-2294&rft.eissn=1559-2308&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1080%2F15592294.2023.2178802&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_15592294_2023_2178802
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1559-2294&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1559-2294&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1559-2294&client=summon